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http://www.biomedcentral.com/1471-2474/14/278RESEARCH ARTICLE Open AccessThe effects of commercially available footwear on
foot pain and disability in people with gout: a
pilot study
Keith Rome1*, Sarah Stewart1, Alain C Vandal2,3, Peter Gow4, Peter McNair1 and Nicola Dalbeth2,4,5Abstract
Background: There is limited evidence on non-pharmacological interventions for gout. The aim of the study was
to determine whether a footwear intervention can reduce foot pain and musculoskeletal disability in people with
gout.
Methods: Thirty-six people with gout participated in a prospective intervention study over 8 weeks. Participants
selected one of 4 pairs of shoes and thereafter wore the shoes for 8 weeks. The primary outcome was foot pain
using a 100 mm visual analogue scale. Secondary outcomes related to function and disability were also analysed.
Results: The Cardio Zip shoe was selected by 58% of participants. Compared with baseline, overall scores for all
shoes at 8-weeks demonstrated a decrease in foot pain (p = 0.03), general pain (p = 0.012), Health Assessment
Questionnaire (HAQ)-II (p = 0.016) and Leeds Foot Impact Scale (LFIS) impairment subscale (p = 0.03). No significant
differences were observed in other patient reported outcomes including patient global assessment, LFIS activity
subscale, and Lower Limb Task Questionnaire subscales (all p > 0.10). We observed significant improvements
between baseline measurements using the participants’ own shoes and the Cardio Zip for foot pain (p = 0.002),
general pain (p = 0.001), HAQ-II (p = 0.002) and LFIS impairment subscale (p = 0.004) after 8 weeks. The other three
shoes did not improve pain or disability.
Conclusions: Footwear with good cushioning, and motion control may reduce foot pain and disability in people
with gout.
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Gout is an inflammatory arthritis that occurs due to the
deposition of monosodium urate crystals in joints and peri-
articular tissues [1]. Gout displays a striking predilection to
affect the feet, particularly the first metatarsophalangeal
joint (1MTPJ), Achilles tendon, midfoot and ankle [2-6].
People with gout experience greater foot pain, impairment
and disability than age-matched controls [7]. This degree
of foot-related pain, impairment and disability is similar to
that reported in people with early and established rheuma-
toid arthritis (RA) [8,9].* Correspondence: krome@aut.ac.nz
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reproduction in any medium, provided the orThe non-pharmacological management goals for people
with foot-related rheumatic diseases are pain manage-
ment, preservation of foot function and patient mobility
[10,11]. One of the therapeutic components that may
achieve these goals is footwear. Our group has reported
that poorly fitting shoes are linked to foot pain in gout
and those with poor footwear have higher foot-related im-
pairment [12]. We further reported that people with gout
frequently wear shoes that are either too long or too short,
have little cushioning and are more than 12 months old
[12]. To date, no research has examined footwear as an
intervention for people with gout. The aim of this study
was to determine whether a footwear intervention can re-
duce foot pain and musculoskeletal disability in people
with gout.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A prospective intervention study design was utilised.
Thirty-six participants were recruited from the rheumatol-
ogy and podiatric rheumatology clinics based in Auckland
District Health Board and Counties Manukau District
Health Boards, Auckland, New Zealand (Figure 1). Partici-
pants included in the study (i) were over 18 years of age,
(ii) had a history of gout according to ACR classification
criteria [13], and (iii) were able to walk a minimum of
10 m without the use of a walking aid. People were ex-
cluded in the study if they had (i) received any medication
for foot pain in the previous 4 weeks, (ii) an acute gout
flare at the time of assessment, (iii) history of surgery to
the foot, or (iv) received treatment with foot orthoses or
footwear within the previous 3 months. The Northern Re-
gional X Ethics approved this study and local institutionalFigure 1 Flow-chart of recruitment of participants.approval was also obtained. All participants provided writ-
ten informed consent before inclusion into the study. The
study was registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12612000735853).
Based upon data from a previous study examining the
primary outcome: foot pain, for a reduction of 20 percent-
age points, with the power set at 80% and a per compari-
son significance level of 5%, 36 participants were required
[14]. McNemar’s test was used for this determination, and
is equivalent to the test of a single footwear pair contrast
in the planned analysis. This was deemed sufficient for the
purpose of sample size determination.
Footwear characteristics
Four black, laced walking shoes were selected for the
study: Dunlop Asteroid, Dunlop Apollo, Helix Viper and
Figure 2 The four study shoes: A. Dunlop Asteroid; B. Helix Viper; C. Dunlop Apollo; D. ASICS Cardio Gel Zip.
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tics were recorded for each shoe using a previously vali-
dated footwear assessment form [15], and are shown in
Table 1. These shoes provided variations in footwear char-
acteristics related to shock attenuation, motion control and
width. Motion control included fixation of the upper to the
foot, heel counter stiffness, and midfoot rigidity [15]. To
develop a continuous scale to assess the quality of footwear
in relation to motion control properties, each categoryTable 1 Characteristics of study shoes1
Characteristic Cardio zip V
Upper materials Leather & Synthetic S
Outsole materials Rubber P
Tread pattern Textured T
Weight (kg) 0.406 0
Length (cm) 29.5 2
Heel Height (cm) 3.9 3
Forefoot height (cm) 2.3 2
Longitudinal Profile (cm) 1.6 1
Last (°) 12 1
Fixation of upper to sole Slip lasted B
Forefoot sole flexion point At level of MTPJs P
Density Dual S
Heel counter stiffness Rigid M
Midfoot sole sagittal stability Moderate M
Midfoot sole frontal stability Moderate M
Motion Control Scale (0–11) 9 4
Presence of cushioning Heel/forefoot H
Lateral midsole hardness2 Firm (57) F
Medial midsole hardness2 Firm (53) F
Heel sole hardness2 firm (56) F
1All characteristics measured from standard shoe size 11, 2Sole hardness measuredfrom the motion control properties items were scored ran-
ging from 0 to 11. Footwear which scores 11 would be con-
sidered to possess optimal motion control properties [15].
At baseline (visit 1), the following clinical features were
recorded: the number of foot tophi, the presence and site
of subcutaneous tophi, age, gender, ethnicity, body mass
index (BMI), disease duration, age of first episode, current
pharmacological management, serum urate levels, age at


















irm (54) Firm (56) Soft (49)
irm (57) Firm (44) Firm (53)
irm (64) Hard (59) Firm (65)
using a durometer.
Table 2 Baseline clinical characteristics
Value
Age, years, mean (SD) 57 (13)
Male, n (%) 33 (92%)




BMI, (kg/m2), mean (SD) 34 (8)
Cardiovascular disease, n (%) 16 (44%)
Type 2 diabetes, n (%) 7 (19%)
Diuretic use, n (%) 9 (25%)
Urate-lowering therapy use, n (%) 34 (94%)
Colchicine use, n (%) 23 (64%)
Prednisone use, n (%) 10 (28%)
NSAID use, n (%) 22 (61%)
Serum urate, mmol/l, mean (SD) 0.39 (0.13)
Disease duration, years, mean (SD) 15 (11)
Age at first episode, years, mean (SD) 42 (19)
Self-reported flares in preceding 2 months, mean (SD) 3.9 (10.8)
Days off work in last two months, mean (SD) 0.3 (1.5)
In paid employment, n (%) 17 (47%)
Aspirate proven, n (%) 11 (31%)
Foot tophus count, mean (SD) 1.3 (1.8)
Total tophus count, mean (SD) 4.5 (4.1)
Any subcutaneous tophus, n (%) 26 (72%)
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cardiovascular disease and diabetes. The primary outcome
for the study was foot pain using a 100 mm VAS pain
scale. Secondary outcome measures included HAQ-II
[16], general pain score (100 m VAS) and patient global
assessment scale (100 mm VAS). The level of lower limb
function was evaluated using the Lower Limb Task Ques-
tionnaire [17]. We measured foot disability and impair-
ment using the 2 subscales of the Leeds Foot Impairment
Score (LFIS): foot impairment/footwear restriction
(LFISIF; range 0–21) and activity limitation/participation
restriction (LFISAP; range 0–29) [18].
Study visits
At visit 1, all participants tried each of the four shoes in
a randomly determined order. Randomization involved
the presentation of one of a series of sealed envelopes
indicating the order in which the footwear was to be
assessed by the participant. The exterior of the footwear
was masked with tape so the brand name and logos of
the shoe would not be recognised. The masking was
small so they did not cover any of the design features. In
each pair of shoes, participants were asked to complete a
circuit that included walking on carpet, on a hard level
surface and ascending and descending stairs. To reduce
fatigue, each participant was allowed to rest for 5 minutes
between footwear. After each circuit, the participant was
asked to consider the comfort, fit, style, sole and weight in
relation to their normal footwear with a view to choosing
a new pair of shoes that they would wear for the following
8 weeks.
At the completion of the baseline assessment, partici-
pants were asked to wear the shoes they chose for 8 weeks
(visit 2). Each participant was given a diary to complete
over this period, and were asked to record the amount
of time the footwear was worn each day and to note any
adverse events.
Data analysis
Gender, ethnicity, clinical characteristics such as current
pharmacological management, history of hypertension,
cardiovascular disease, diabetes, renal impairment were
described as n (percentages). All other demographic char-
acteristics were described as mean (SD).
Mixed effects regression was used as the primary ana-
lysis of all prospective study outcomes, using participants
as random effects, and visit and footwear interaction as
fixed effects. Mixed effects (ME) regression is a generalisa-
tion of paired t-tests. In particular, the p-values and confi-
dence intervals for footwear-specific changes in Table 2
bear the same interpretation as those that would be
obtained from paired-t inference. They are different in
value however, as they use all data for full efficiency. ME
regression enables the use of Visit 1 data from allparticipants to test for any specific footwear effect. This
stands in contrast to using only the Visit 1 data of partici-
pants who selected a particular type of footwear, as would
happen with an unmodified paired t-test. In doing so, ME
regression still accounts for the association between Visit
1 and Visit 2 measurements for any given type of foot-
wear. ME regression also enables correct inference regard-
ing footwear differences and overall differences regardless
of footwear type, all under a single inferential setting.
The fixed effect structure (visit 1 with no interaction vs.
visit 2 in interaction with footwear) was designed to reflect
the study design, since baseline measurements were based
on participants’ own shoes. Means and their differences
were reported as point estimates and confidence intervals.
P-values were reported to test the fitted models against
three null hypotheses: that of no change between visits for
a particular type of footwear; that of equal change between
visits for each type of footwear; and that of no change be-
tween visits for any type of footwear. Missing outcome
data requires no special treatment in mixed regression set-
tings. The significance level for testing was established at
0.05 against two-sided alternatives. Per comparison error
rate (no adjustment for multiple testing) was used, but









Foot Pain VAS Visit 1 (Own) 37.8
Visit 2 (Asteroid) 20.0 −17.8 −44.0 8.3 0.19 0.47 0.028
Visit 2 (Apollo) 34.6 −3.2 −29.4 22.9 0.81
Visit 2 (Helix) 34.7 −3.1 −33.3 27.0 0.84
Visit 2 (Cardio Zip) 16.0 −21.9 −34.5 −9.3 0.002
Pain VAS Visit 1 (Own) 35.7
Visit 2 (Asteroid) 45.1 9.4 −11.5 30.2 0.39 0.07 0.012
Visit 2 (Apollo) 34.0 −1.7 −22.6 19.1 0.87
Visit 2 (Viper) 33.3 −2.4 −26.5 21.6 0.84
Visit 2 (Cardio Zip) 16.3 −19.4 −29.3 −9.6 0.001
Patient global assessment VAS Visit 1 (Own) 37.9
Visit 2 (Asteroid) 30.9 −7.1 −28.2 14.1 0.52 0.61 0.39
Visit 2 (Apollo) 37.1 −0.8 −22.0 20.4 0.94
Visit 2 (Viper) 16.2 −21.7 −46.1 2.6 0.09
Visit 2 (Cardio Zip) 32.5 −5.4 −15.6 4.8 0.31
HAQ-II Visit 1 (Own) 0.8
Visit 2 (Asteroid) 0.7 −0.1 −0.5 0.2 0.38 0.07 0.016
Visit 2 (Apollo) 1.0 0.2 −0.1 0.5 0.15
Visit 2 (Helix) 0.7 −0.1 −0.5 0.2 0.55
Visit 2 (Cardio Zip) 0.5 −0.3 −0.4 −0.1 0.002
LFIS Visit 1 (Own) 10.6
Visit 2 (Asteroid) 11.3 0.7 −2.6 4.0 0.68 0.37 0.03
(Impairment/footwear) Visit 2 (Apollo) 9.1 −1.6 −4.8 1.7 0.35
Visit 2 (Viper) 8.2 −2.4 −6.2 1.4 0.22
Visit 2 (Cardio Zip) 8.1 −2.5 −4.1 −1.0 0.004
LFIS Visit 1 (Own) 15.6
Visit 2 (Asteroid) 10.9 −4.7 −9.5 0.2 0.07 0.46 0.11
(Activities/Participation) Visit 2 (Apollo) 15.6 0.0 −4.8 4.9 1.00
Visit 2 (Viper) 11.0 −4.6 −10.2 1.0 0.12
Visit 2 (Cardio Zip) 13.7 −1.8 −4.1 0.4 0.12
LFIS (total) Visit 1 (Own) 26.2
Visit 2 (Asteroid) 22.6 −3.6 −10.8 3.5 0.33 0.80 0.064
Visit 2 (Apollo) 24.5 −1.7 −8.8 5.5 0.65
Visit 2 (Viper) 19.1 −7.1 −15.4 1.2 0.11
Visit 2 (Cardio Zip) 21.8 −4.4 −7.7 −1.0 0.02
LLTQ Visit 1 (own) 28.6
Visit 2 (Asteroid) 33.3 4.6 0.1 9.1 0.05 0.08 0.11
Visit 2 (Apollo) 24.6 −4.1 −8.6 0.4 0.09
(Daily) Visit 2 (Viper) 28.7 0.1 −5.1 5.2 0.98
Visit 2 (Cardio Zip) 29.8 1.1 −1.0 3.2 0.30
LLTQ Visit 1 (Own) 18.0
Visit 2 (Asteroid) 24.0 6.0 −1.9 13.8 0.15 0.11 0.11
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Table 3 Differences between visit 1 and visit 2 for patient-reported outcomes (Continued)
Visit 2 (Apollo) 13.8 −4.2 −12.1 3.6 0.30
(Recreational) Visit 2 (Viper) 21.3 3.2 −5.8 12.3 0.49
Visit 2 (Cardio Zip) 14.1 −3.9 −7.6 −0.2 0.05
Note: The p-values address the following null hypotheses. Footwear specific change: tests against a null hypothesis of no change between visits 1 and 2 for the
target footwear only; Change differs by footwear: tests against a null hypothesis of similar change between visits 1 and 2 for any footwear; any change: tests
against a null hypothesis of no change between visits 1 and 2.
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for the production of unbiased confidence intervals was
set at 0.95. Analyses were performed using SPSS V20.0, R
version 2.15.0 for Windows and SAS/STAT software, Ver-
sion 9.3 of the SAS System for Windows.
Results
Clinical characteristics at baseline are shown in Table 2.
Participants were predominantly middle-aged men, with
high rates of obesity and co-morbidities such as hyper-
tension, diabetes and cardiovascular disease. Subcutane-
ous tophi affecting the 1MTPJ were observed in 12/36
(33%) participants and in the Achilles tendon in 12/36
(33%) participants. Thirty four (94%) participants were
on urate lowering therapy, most commonly allopurinol
in 29/34 (85%).
High scores for foot pain, disability and impairment
were observed at visit 1 (Table 3). Over 50% of the partici-
pants’ currently owned shoes were 12 months old or older.
Based upon participants’ preference, the Cardio Zip (n =
21, 58%) was the most popular new shoe, followed by the
Apollo (n = 7, 19%), then Asteroid (n = 5, 14%) and finally
the Viper (n = 3, 8%). Follow-up data including study diar-
ies were available for 30 (83%) participants. Six partici-
pants (17%) were lost to follow-up, with 2 participants
unable to attend due to family commitments, 1 with gout
flare, 1 dissatisfied with shoes, and 2 unable to be
contacted. The 30 participants who completed the study
diaries wore their chosen shoes for a mean (SD) of 26 (10)
hours per week. No adverse events associated with the
shoes were reported. During the 8 week trial, one partici-
pant commenced allopurinol therapy.
The patient-reported outcomes in the entire group at
baseline and follow-up are shown in Table 3. After 8 weeks,
there were significant improvements from baseline in the
entire group in foot pain (p = 0.03), general pain (p =
0.012), HAQ II scores (p = 0.016) and LFISIF (p = 0.03). No
significant differences were observed in the patient global
assessment scores (p = 0.39), LFISAP (p = 0.11) activities of
daily living using the Lower Limb Task Questionnaire (p =
0.11) or recreational activities using the Lower Limb Task
Questionnaire (p = 0.11). We found significant improve-
ments between the baseline visit scores (participants own
shoes) and eight week scores for the Cardio Zip for foot
pain (p = 0.002), general pain (p = 0.001), HAQ-II (p =
0.002) and LFISIF (p = 0.004). Improvements in foot painor other patient reported outcomes were not observed in
the other shoes. Figure 3 illustrates the differences of the
four shoes for foot pain, general pain, HAQ-II and LFISIF.
Discussion
This is the first intervention study examining the role of
footwear in people with gout. In this study, most partici-
pants selected the Cardio Zip. We found that the Cardio
Zip shoe significantly reduced foot pain, general pain
and foot impairment over 8 weeks.
A number of features in the Cardio Zip shoe may be
responsible for the reduction in pain and disability. The
medial size zip closure in the Cardio Zip shoe enhances
the ease of putting on and taking off the shoe. The Car-
dio Zip shoe also uses a dual-density midsole system to
control motion. Barton [15] reported that the motion
control properties of footwear are considered an import-
ant shoe feature in the management of patients with RA
and musculoskeletal injuries. Another feature of the Car-
dio Zip shoe that may have reduced foot pain was the
use of gel cushioning in the heel and forefoot regions to
improve shock attenuation. This shoe element was not
present in the other three shoe types. Dufour [19]
reported that shoes that have softer out-soles, and mid-
soles, or insoles that use elements of gel, foamed polyur-
ethane, or air chambers can smooth (low pass filter) the
shock wave associated with foot-strike. Finally, the
Cardio Zip shoe midsole/outsole has a 'rocker' type sys-
tem to create a smoother heel to toe transition during
the gait cycle while maintaining both stability and comfort.
Previous studies have reported that the toe rocker-soled
shoe is thought to reduce pain by decreasing forefoot
loading and promoting a normal heel-toe motion during
gait [20-22]. Cho [20] reported that rocker-soled shoes
with comfortable insoles may be enough to reduce foot
pain and increase foot function for people with RA.
We found our participants wore the chosen shoes an
average of 26 hours/week over the 8-week trial, demon-
strating good adherence. Similar findings have been
reported in RA studies using foot orthoses [23-27]. Patient
acceptability and adherence are integral components of
treatment success with footwear or foot orthoses interven-
tions [28]. Williams [10] also reported significant improve-
ments in foot pain associated with RA when patients were
involved in the choice of their shoes, as compared to hav-
ing a particular shoe prescribed to them. Given the
Figure 3 Patient reported outcomes from visit 1 to visit 2.
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with gout [12], it would be important that patients are ed-
ucated in the key elements/concepts that they should look
for when buying shoes in the retail sector. In agreementwith our previous findings [12], the majority of partici-
pants’ own shoes would be regarded as old, and hence
likely to be limited in their ability to control foot motion,
and cushion the foot sufficiently.
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searcher collecting the outcome measures was not blinded
to the shoes that the patient had chosen. However, the
study protocol stated that the researcher should make no
comments concerning the patient’s choice. The period
over which shoes were worn was short and the shoes
could be considered as being in a relatively new state after
8 weeks wear. A longer study would allow greater under-
standing of the effects of wear on the structural and mech-
anical properties of materials responsible for motion
control and shock absorption, and the influence of these
properties on long-term pain reduction. The high fre-
quency of tophaceous disease reflects the hospital setting
and the complexity of gout seen in Auckland, New Zealand
particularly in the Māori and Pacific people. This may limit
the generalisability of the findings to other populations with
gout. Furthermore, it is unclear whether people with differ-
ent stages of the disease would benefit from a similar inter-
vention with footwear. Using the self-reported diaries to
assess adherence was patient-reported only and therefore
may be susceptible to bias/error.
Conclusions
In conclusion, this is the first reported trial of a footwear
intervention for people with gout. The findings suggest that
a shoe with adequate motion control, cushioning, stability
may reduce foot pain and musculoskeletal disability. Clini-
cians should consider footwear characteristics when advis-
ing people with gout on foot care. In addition to excellent
control of serum urate concentrations using pharmaco-
logical treatment, footwear interventions may be of benefit
in reducing foot pain and disability in people with gout. Fu-
ture research is needed to observe the long-term impact of
footwear on foot pain and musculoskeletal disability in
people with gout. Future work should also consider cost-
effectiveness analyses of footwear including studies to assess
the impact of gout on indirect costs and quality of life on
people with gout and their families.
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